Windlas Biotech Grants 37,000 Employee Stock Options

Windlas Biotech's Nomination Committee approved grants under two employee stock benefit schemes on May 21, 2026.
The company granted 15,750 options under its ESOS 2023 scheme and 21,250 units under its Windlas Plan 2025.
Options vest over 1-4 years and can be exercised for up to 4 years after vesting, potentially issuing 37,000 new shares.
This is a regulatory disclosure under SEBI LODR Regulation 30 for stock exchange compliance.